NCT03829917View on ClinicalTrials.gov

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 31, 2020

Conditions
Cutaneous Leishmaniasis, American
Interventions
DRUG

Miltefosine and Paromomycin

28 days of miltefosine plus 28 days of Paromomycin cream

DRUG

miltefosine

28 days of miltefosine

DRUG

paromomycin

28 days of paromomycin creaam

Trial Locations (1)

00000

Hopital, Dermatologico, Jorochito

All Listed Sponsors
collaborator

Hospital Dermatológico de Jorochito

UNKNOWN

collaborator

Ministerio de Salud de Bolivia, Programa Nacional de Leishmaniasis

UNKNOWN

collaborator

Alfred Berman Foundation

UNKNOWN

lead

Fundacion Nacional de Dermatologia

OTHER

NCT03829917 - Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis | Biotech Hunter | Biotech Hunter